Christian G Chaussy, Stefan Thueroff


Prostate cancer is diagnosed 10 years earlier and men live almost 4 years longer than 30 years ago. This means that the therapeutic necessity is more than double the time than it was then.  These changing trends in age and extent of malignancy at diagnosis have revealed limitations in conventional curative therapies for prostate cancer, including a significant risk of cancer recurrence, and the risk of long-term genitourinary morbidity and its detrimental impact on patient quality of life (QOL). Greater awareness of the limitations in radical prostatectomy, external radiotherapy and brachytherapy have prompted the search for alternative curative therapies that offer comparable rates of cancer control and less treatment-related morbidity to better preserve QOL. High intensity focused ultrasound (HIFU) possesses characteristics that make it an attractive curative therapy option. HIFU is a non-invasive approach that uses precisely delivered ultrasound energy to achieve prostate tissue necrosis without radiation or surgical excision. In current urological oncology, HIFU is used clinically in the treatment of prostate cancer, and is under experimental investigation for therapeutic use in multiple malignancies. Clinical research on HIFU therapy for localized prostate cancer began in the 1990s, and there have now been approximately 40,000 prostate cancer patients treated with HIFU. Neoadjuvant transurethral resection of the prostate (TURP) has been combined with HIFU since 2000 to reduce prostate size, facilitate tissue destruction, and to minimize side effects. Advances in imaging technologies are expected to further improve the already superior efficacy and morbidity outcomes, and ongoing investigation of HIFU as a focal therapy in salvage and palliative indications are serving to expand the role of HIFU as a highly versatile non-invasive therapy for prostate cancer.



HIFU: High Intensity focused Ultrasound, less invasive PCa Therapy, castration resistant therapy, focal therapy

Full Text:



Chaussy CG. Ultrasonidos De Alta Intensidad Focalizados (HIFU) Para El Tratamiento Local Del Cancer De Prostata: Papel Actual. Arch Esp Urol,2011,64(6): 493-506.

Chaussy CH, Thuroff S. The status of high-intensity focused ultrasound in the treatment of localized prostate cancer and the impact of a combined resection. Curr Urol Rep,2003,4:248–252.

Chaussy C, Thuroff S. Results and side effects of high intensity focused ultrasound in localized prostate cancer. J Endourol,2001,15:437–440, 447–448.

Chaussy Ch, Thuroff S. The use of high-intensity focused ultrasound in prostate cancer. In: O Ukimura and I.S.Gill. Contemporary Interventional Ultrasonography in Urology. London: Springer, 2009:63–74.

Blana A, Murat FJ, Walter B, Thuroff S, Wieland WF, Chaussy C, Gelet A. First Analysis of the Long-Term Results with Transrectal HIFU in Patients with Localised Prostate Cancer. Eur Urol,2008,53(6):1194-1201.

Chaussy CG, Thüroff SF. Robotic high-intensity focused ultrasound for prostate cancer: what have we learned in 15 years of clinical use? Curr Urol Rep,2011,12(3):180-7.

Lynn JG and Putman TJ. Histological and cerebral lesions produced by focused ultrasound. Am J Pathol,1944,20:637-649.

ter Haar G. Intervention and therapy. Ultrasound Med Biol,2000,23(1 Suppl): S51-S54.

Poissonnier L, Gelet A, Chapelon JY, Bouvier R, Rouviere O, Pangaud C, Lyonnet D, Dubernard JM. Results of transrectal focused ultrasound for the treatment of localized prostate cancer (120 patients with PSA

Chaussy C, Thüroff S. High-intensity focused ultrasound in the management of prostate cancer. Expert Rev Med Devices,2010,7(2):209-17.

Chapelon JY, Margonari J, Theillère Y, Gorry F, Vernier F, Blanc E, Gelet A. Effects of high-energy focused ultrasound on kidney tissue in the rat and the dog. Eur Urol,1992,22:147-152.

Uchida T, Sanghvi NT, Gardner TA, Koch MO, Ishii D, Minei S, Satoh T, Hyodo T, Irie A, Baba S. Transrectal high-intensity focused ultrasound for treatment of patients with stage T1b-2n0m0 localized prostate cancer: a preliminary report. Urology,2002,59(3):394-8; discussion 398-9.

Chapelon JY, Cathignol D, Cain C, Ebbini E, Kluiwstra JU, Sapozhnikov OA, Fleury G, Berriet R, Chupin L, Guey JL. New piezoelectric transducers for therapeutic ultrasound. Ultrasound Med Biol,2000,26:153-159.

Curiel L, Chavrier F, Souchon R, Birer A, Chapelon JY. 1.5-D high intensity focused ultrasound array for non-invasive prostate cancer surgery. IEEE Trans Ultrason Ferroelectr Freq Control,2002,49(2):231-42.

Tan JS, Frizzell LA, Sanghvi NT, Seip R, Wu JS, Kouzmanoff, JT. Design of focused ultrasound phased arrays for prostate treatment, Ultrasonics Symp Proc IEEE,2000,2:1247–1251.

Oosterhof GO, Cornel EB, Smits GA, Debruyne FM, Schalken JA. Influence of high intensity focused ultrasound on the development of metastases. Eur Urol,1997,32:91–95.

Foster RS, Bihrle R, Sanghvi N, Fry F, Kopecky K, Regan J, Eble J, Hennige C, Hennige LV, Donohue JP. Production of prostatic lesions in canines using transrectally administered high intensity focused ultrasound. Eur Urol,1993,23 330–336.

Gelet A, Chapelon JY, Margonari J, Theillere Y, Gorry F, Cathignol D, Blanc E. Prostatic tissue destruction by high-intensity focused ultrasound: experimentation on canine prostate. J Endourol,1993,7(3):249-53.

Chaussy C, Thüroff S, Rebillard X, Gelet A. Technology insight: High-intensity focused ultrasound for urologic cancers. Nat Clin Pract Urol. 2005 Apr;2(4):191-8.

Rebillard X, Davin JL, Soulié M; Comité de Cancérologie de l'Association Française d'Urologie. Treatment by HIFU of prostate cancer: survey of literature and treatment indications. Prog Urol,2003,13:1428–1456.

Chaussy CG, Thüroff S. Robot-assisted high-intensity focused ultrasound in focal therapy of prostate cancer. J Endourol,2010,24(5):843-847.

Ahmed HU, Dickingson L, Charman S, Weir S, McCartan N, Hindley RG, Freeman A, Kirkham AP, Sahu M, Scott R, Allen C, Van der Meulen J, Emberton M. Focal Ablation Targeted to the Index Lesion in Multifocal Localised Prostate Cancer: A Prospective Development Study. Eur Urol. 2015, Dec; 68(6): 927-36

Beerlage HP, van Leenders GJ, Oosterhof GO, Witjes JA, Ruijter ET, van de Kaa CA, Debruyne FM, de la Rosette JJ. High-intensity focused ultrasound (HIFU) followed after one to two weeks by radical retropubic prostatectomy: results of a prospective study. Prostate,1999,1;39(1):41-46.

Rouviere O, Lyonnet D, Raudrant A, Colin-Pangaud C, Chapelon JY, Bouvier R, Dubernard JM, Gelet A. MRI appearance of prostate following transrectal HIFU ablation of localized cancer. Eur Urol,2001,40:265–274.

Hynynen K, Freund WR, Cline HE, Chung AH, Watkins RD, Vetro JP, Jolesz FA. A clinical, noninvasive, MR imaging-monitored ultrasound surgery method. Radiographics,1996,16:185–195.

Damianou C, Pavlou M, Velev O, Kyriakou K, Trimikliniotis M. High intensity focused ultrasound ablation of kidney guided by MRI. Ultrasound Med Biol,2004,30 397–404.

Wu T, Felmlee JP, Greenleaf JF, Riederer SJ, Ehman RL. Assessment of thermal tissue ablation with MR elastography. Magn Reson Med,2001,45:80–87.

Vaezy S, Shi X, Martin RW, Chi E, Nelson PI, Bailey MR, Crum LA. Real-time visualization of high-intensity focused ultrasound treatment using ultrasound imaging. Ultrasound Med Bio,2001,27:33–42.

Sedelaar JP, Aarnink RG, van Leenders GJ, Beerlage HP, Debruyne FM, Wijkstra H, de La Rosette JJ. The application of three-dimensional contrast-enhanced ultrasound to measure volume of affected tissue after HIFU treatment for localized prostate cancer. Eur Urol,2000,37: 559-568.

Lu J, Ying H, Sun Z, Motamedi M, Bell B, Sheppard LC. In vitro measurement of speed of sound during coagulate tissue heating. Ultrasonics Symp Proc IEEE,1996, 2:1299–1302.

Gelet A, Chapelon JY, Poissonnier L, Bouvier R, Rouvière O, Curiel L, Janier M, Vallancien G. Local recurrence of prostate cancer after external beam radiotherapy: early experience of salvage therapy using high-intensity focused ultrasonography. Urology, 2004,63(4):625-629.

Chaussy C, Thueroff S. Complete remission in metastatic prostate cancer after combined local and systemic therapy. Urology,2006,68:197–198.

Ficarra V, Antoniolli SZ, Novara G, Parisi A, Fracalanza S, Martignoni G, Artibani W. Short-term outcome after high-intensity focused ultrasound in the treatment of patients with high-risk prostate cancer. BJU Int,2006,98(6):1193-1198.

ASTRO. Consensus Statement. Guidelines for PDSA following radiation therapy. Int J Radiat Oncol Biol Phys,1997,37,1035–1041.

Chaussy CG, Thueroff S. Transrectal high-intensity focused ultrasound for local treatment of Prostate Cancer. Urologe A,2009;48(7):710–718.

Vallancien G, Prapotnich D, Cathelineau X, Baumert H, Rozet F. Transrectal focused ultrasound combined with transurethral resection of the prostate for the treatment of localized prostate cancer: feasibility study. J Urol,2004,171(6 Pt 1):2265-2267.

Agarwal PK, Sadetsky N, Konety BR, Resnick MI, Carroll PR; Cancer of the Prostate Strategic Urological Research Endeavor (CaPSURE). Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. Cancer,2008,112(2):307-314.

Gelet A, Chapelon JY, Bouvier R, Souchon R, Pangaud C, Abdelrahim AF, Cathignol D, Dubernard JM. Treatment of prostate cancer with transrectal focused ultrasound: early clinical experience. Eur Urol,1996,29(2):174-183.

Gelet A, Chapelon JY, Bouvier R, Pangaud C, Lasne Y. Local control of prostate cancer by transrectal high intensity focused ultrasound therapy: preliminary results. J Urol,1999,161(1):156-162.

Gelet A, Chapelon JY, Bouvier R, Rouvière O, Lasne Y, Lyonnet D, Dubernard JM. Transrectal high-intensity focused ultrasound: minimally invasive therapy of localized prostate cancer. J Endourol, 2000,14(6):519-528.

Richaud P, Moreau JL, Beuzeboc P, Rébillard X, Villers A, Peyromaure M, Cornud F, Soulié M, Davin JL. Follow-up of prostate cancer. Guidelines of the French Urological Association Oncology Committee. Prog Urol,2005,15,586–592.

Gelet A, Chapelon JY, Bouvier R, Rouvière O, Lyonnet D, Dubernard JM. Transrectal high intensity focused ultrasound for the treatment of localized prostate cancer: factors influencing the outcome. Eur Urol,2001,40(2):124-129.

Blana A, Rogenhofer S, Ganzer R, Lunz JC, Schostak M, Wieland WF, Walter B. Eight years’ experience with high-intensity focused ultrasonography for treatment of localized prostate cancer. Urology,2008,72(6):1329–1333.

Poissonnier L, Chapelon JY, Rouvière O, Curiel L, Bouvier R, Martin X, Dubernard JM, Gelet A.Control of prostate cancer by transrectal HIFU in 227 patients. Eur Urol,2007,51:381–387.

Blana A, Brown SCW, Chaussy C, Conti GN, Eastham JA, Ganzer R, Murat FJ, Rebillard X, Rewcastle JC, Robertson CN, Thueroff S, Ward JF, Gelet A. Primary prostate HIFU without pretreatment hormone therapy: biochemical survival of 763 patients tracked with the @-Registry. Eur Urol,2009,8(4):333(Abstract 850).

D’Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate specific antigen era. J Clin Oncol,2003,21(11):2163–2172.

Ganzer R, Rogenhofer S, Walter B, Lunz JC, Schostak M, Wieland WF, Blana A. PSA nadir is a significant predictor of treatment failure after high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. Eur Urol,2008,53:547-553.

Thüroff S, Chaussy C, Vallancien G, Wieland W, Kiel HJ, Le Duc A, Desgrandchamps F, De La Rosette JJ, Gelet A. High-intensity focused ultrasound and localized prostate cancer: efficacy results from the European multicentric study. J Endourol,2003,17(8):673-677.

Kupelian PA, Elshaikh M, Reddy CA, Zippe C, Klein EA.. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol,2002,20:3376–3385.

Kuban DA, Elshaikh M, Reddy CA, Zippe C, Klein EA. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys,2003,57 915–928.

Potters L, Klein EA, Kattan MW, Reddy CA, Ciezki JP, Reuther AM, Kupelian PA. Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation. Radiother Oncol,2004,71:29–33.

Crouzet S, Rebillard X, Chevallier D, Rischmann P, Pasticier G, Garcia G, Rouviere O, Chapelon JY, Gelet A. Multicentric oncologic outcomes of high-intensity focused ultrasound for localized prostate cancer in 803 patients. Eur Uro, 2010,58(4):559-566.

Ahmed HU, Zacharakis E, Dudderidge T et al: High-intensity focused ultrasound in the treatment of primary prostate cancer: the first UK series. Br J Cancer, 2009; 101: 19–26

Mearini L, D’Urso L, Collura D et al: Visually directed transrectal high intensity focused ultrasound for the treatment of prostate cancer: a preliminary report on the Italian experience. J Urol, 2009;181: 105-11

Muto S, Yoshii T, Saito K et al: Focal therapy with high-intensity focused ultrasound in the treatment of localized prostate cancer. Jpn J Clin Oncol, 2008; 38: 192–99

Uchida T, Baba S, Irie A et al: Transrectal high-intensity focused ultrasound in the treatment of localized prostate cancer: a multicenter study. Hinyokika Kiyo, 2005; 51: 651–58

Uchida T, Ohkusa H, Nagata Y et al: Treatment of localized prostate cancer using high-intensity focused ultrasound. BJU Int, 2006; 97: 56–61

Uchida T, Shoji S, Nakano M et al: Transrectal high-intensity focused ultrasound for the treatment of localized prostate cancer: eight-year experience. Int J Urol, 2009; 16: 881–86

Barkin J: Hight intensity focused Ultrasound (HIFU). Can J Urol, 2011; 18: 5634–43

Chaussy CG, Thüroff S .High-intensive focused ultrasound in localized prostate cancer. J Endourol,2000,14: 293–299.

Thüroff S, Chaussy CG. High-intensity focused ultrasound: complications and adverse events. Mol Urol,2000,4:183-187.

Thüroff S. High-Intensity focused ultrasound for prostate cancer. In: Li-Ming Su and Stephen C.Young (eds). Early Diagnosis and Treatment of Cancer: Prostate Cancer:Saunders Elsevier,2008 Chapter 9:177-192.

Thüroff S, Chaussy C, Gelet A. Focused ultrasound (HIFU) in the treatment of prostate cancer. energy/efficacy correlation.WCE Congress, 2001. J Endourol,2001,15(1 Suppl):S32 (Abstract A3-P10).

Chaussy CG, Thueroff SF. HIFU treatment of locally advanced prostate cancer. J Endourol,2010,24(1 Suppl):PS12–2.

Chaussy C, Thuroff S, Nanieva R. Hormone resistant prostate cancer treated by robotic high intensive ultrasound. J Urol,2010,(183 Suppl):e262.

Chaussy C, Thüroff S, Bergsdorf T. Local recurrence of prostate cancer after curative therapy. HIFU (Ablatherm) as a treatment option. Urologe A,2006,45(10):1271-1275.

Murat FJ, Poissonnier L, Rabilloud M, Belot A, Bouvier R, Rouviere O, Chapelon JY, Gelet A. Mid-term results demonstrate salvage high-intensity focused ultrasound (HIFU) as an effective and acceptably morbid salvage treatment option for locally radiorecurrent prostate cancer. Eur Urol,2009,55(3):640-647.

Berge V, Baco E, Karlsen SJ. A prospective study of salvage high intensity focused ultrasound for locally radiorecurrent prostate cancer: early results. Scand J Urol Nephrol,2010,44:223–227.

Hayashi M, Shinmei S, Asano K. Transrectal high-intensity focused ultrasound for treatment for patients with biochemical failure after radical prostatectomy. Int J Urol,2008,14:1048-1050.

Zacharakis E, Ahmed HU, Ishag A et al. The feasibility and safety of high intensity focused ultrasound as salvage therapy for recurrent prostate cancer following external beam radiotherapy.

BJU Int., 2008;102:786-92

van Leeuwen PJ, Connolly D, Tammela TL, Auvinen A, Kranse R, Roobol MJ, Schroder FH, Gavin A. Balancing the harms and benefits of early detection of prostate cancer. Cancer,2010,116:4857–4865.

Lee DJ, Ahmed HU, Moore CM, Emberton M, Ehdaie B. Multiparametric magnetic resonance imaging in the management and diagnosis of prostate cancer: current applications and strategies. Curr Urol Rep. 2014 Mar; 15(3):390

Roemeling S, Roobol MJ, Kattan MW, van der Kwast TH, Steyerberg EW, Schröder FH. Nomogram use for the prediction of indolent prostate cancer: impact on screen-detected populations. Cancer,2007,110:2218–2221.

Onik G, Barzell W. Transperineal. 3D mapping biopsy of the prostate: an essential tool in selecting patients for focal prostate cancer therapy. Urol Oncol,2008,26(5):506–510.

Rouvière O, Souchon R, Salomir R, Gelet A, Chapelon JY, Lyonnet D. Transrectal high-intensity focused ultrasound ablation of prostate cancer: effective treatment requiring accurate imaging. Eur J Radiol,2007,63(3):317-327.

Kirkham AP, Emberton M, Allen C. How good is MRI at detecting and characterising cancer within the prostate? Eur Urol,2006,50:1163–1174.

Kim JK, Hong SS, Choi YJ, Park SH, Ahn H, Kim CS, Cho KS. Wash-in rate on the basis of dynamic contrast-enhanced MRI: usefulness for prostate cancer detection and localization. J Magn Reson Imaging,2005,22(5): 639–646.

Haider MA, van der Kwast TH, Tanguay J, Evans AJ, Hashmi AT, Lockwood G, Trachtenberg J. Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. Am J Roentgenol,2007,189(2):323–328.

Uchida T, Illing RO, Cathcart PJ, Emberton M. To what extent does the prostate-specific antigen nadir predict subsequent treatment failure after transrectal high-intensity focused ultrasound therapy for presumed localized adenocarcinoma of the prostate. BJU Int,2006,98:537–539.

Wu F, Wang ZB, Lu P, Xu ZL, Chen WZ, Zhu H, Jin CB. Activated anti-tumor immunity in cancer patients after high intensity focused ultrasound ablation. Ultrasound Med Biol,2004,30(9):1217–1222.

Wu F, Wang ZB, Cao YD, Zhou Q, Zhang Y, Xu ZL, Zhu XQ. Expression of tumor antigens and heat-shock protein 70 in breast cancer cells after high intensity focused ultrasound ablation. Ann Surg Oncol,2007,14(3):1237–1242.

Hu Z, Yang XY, Liu Y, Sankin GN, Pua EC, Morse MA, Lyerly HK, Clay TM, Zhong P. Investigation of HIFU-induced antitumor immunity in a murine tumor model. J Transl Med,2007,5:34.

Lu P, Zhu XQ, Xu ZL, Zhou Q, Zhang J, Wu F. Increased infiltration of activated tumor infiltrating lymphocytes after high intensity focused ultrasound ablation of human breast cancer. Surgery,2009,145(3):286–293.

Lee HM, Hong JH, Choi HY. High-intensity focused ultrasound therapy for clinically localized prostate cancer. Prostate Cancer Prostatic Dis,2006,9(4): 439-443.

Thüroff S, Chaussy C. Focal Therapy of Prostate Cancer. An Emerging Strategy for Minimally Invasive, Staged Treatment. Springer Intl. Publishing, Switzerland 2015

ISBN 978-3-319-14160-2



  • There are currently no refbacks.
Copyright 2016. All rights reserved.